Medican Enterprises Inc. (MDCN:OTC) Acquires A Stake In RBA Pharma Inc.

Detroit, MI -- January 30, 2018 -- InvestorsHub NewsWire -- Medican Enterprises Inc. (MDCN:OTC) is pleased to announce that, pursuant to a press release released last week, it has acquired a 40% equity stake in Montreal-based, RBA Pharma Inc. This biotech company owns the intellectual property rights for one of the most advanced dermal/transdermal delivery systems in the world. Their technology fills a void in the $32 billion global market for advanced skin delivery systems.

RBA Pharma Inc.’s proprietary skin care products are based on a matrix which creates an active dermal drug delivery system, providing the adapted environment that allows the skin to repair itself. This biomimetic hydrogel feels like water to the touch but does not stick to the skin or to wounds. The research has been published in several peer reviewed wound care journals.

To view the website for RBA Pharma Inc., click on the following link:
http://www.rbapharma.com/index-en.html

Ken Williams, CEO of Medican Enterprises Inc., states the following, “this acquisition provides synergies with our other holdings and is a welcome edition. Their delivery systems are second to none so I am expecting them to dominate the $32 billion global market for advanced skin delivery systems.”

Updates will be forthcoming

About Medican Enterprises, Inc.

Our Mission is to lead production, distribution, research & development. Medican seeks to become the world’s largest wholesale supplier of pharmaceutical grade cannabis to the medical marijuana industry. A leader in innovation, quality and variety. Leadership Medican delivers strong operational experience and a significant focus on research and development. Medican is uniquely positioned to capitalize on the market opportunity. Quality and Efficiency Medican produces effective Cannabis strains with standardized potency and verified purity. The company has the highest standards of safety and inspection in all areas of quality control, cultivation, and distribution. A combination of in house Research & Development team's, third party testing which ensures the potency of active ingredients in all products and is free of microbial chemical contaminants. Stringent quality control testing provides lot numbers for precise identification of all products.

For More Information, Ken Williams, CEO | Medican Enterprises, Inc.
T: +1.313.703.7873
E: investors@medican.enterprises
Website: http://www.medican.enterprises

Legal Notice Regarding Forward-Looking Statements:
This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of technical, installation, perming or other problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medican Enterprises Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Medican Enterprises, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.